SeaStar Medical Announces Pricing of $9.0 Million Registered Direct Offering Priced At-the-Market
- None.
- None.
Insights
The private placement and registered direct offering by SeaStar Medical Holding Corporation represents a strategic move to raise capital, indicating an infusion of funds that could be earmarked for research and development, marketing, or operational expansion. The issuance of common stock and warrants dilutes current shareholder value, but the capital raised can potentially lead to long-term growth if invested wisely. The effective offering price of $0.8302 is a critical figure, as it sets the baseline for the warrants' exercise price and could reflect the company's current valuation in the eyes of institutional investors.
Investors should consider the dilutive effect of the new shares and warrants on their holdings. However, the exercise of Series A and Series B warrants could provide additional capital in the future, albeit at the risk of further dilution. The five-year lifespan of Series A warrants suggests a long-term commitment from investors, while the one-year term for Series B warrants indicates a potential for a more immediate cash influx if exercised.
The involvement of Maxim Group LLC as the sole placement agent adds a layer of credibility to the offering, as such firms typically conduct due diligence before associating with a deal. Investors should monitor the closing of the offering and subsequent use of proceeds for indications of the company's strategic direction.
SeaStar Medical Holding's focus on reducing hyperinflammation's impact on vital organs addresses a significant medical need, as hyperinflammation can lead to critical conditions such as sepsis and organ failure. The capital raised through this offering could accelerate the development of their proprietary solutions, potentially benefiting patients with conditions caused by hyperinflammation.
From a research and development perspective, the $9.0 million in gross proceeds may be allocated to clinical trials, which are essential for validating the efficacy and safety of their medical technology. The success of these trials is a pivotal factor for FDA approval and subsequent market adoption. Investors should evaluate the company's research pipeline and the potential market size for its medical technology to gauge the long-term prospects.
Given the complex nature of medical device development and the regulatory hurdles, the actual impact of this capital on the company's progress should be assessed in the context of their current stage of development and the typical costs associated with bringing medical technology to market.
The healthcare sector and specifically medical technology, is highly competitive with continuous innovation. SeaStar Medical Holding's funding initiative could be a response to the need to stay competitive and invest in breakthrough technologies. The company's ability to attract a single institutional investor suggests confidence in its business model and growth potential.
Market analysis should consider the demand for innovative treatments for hyperinflammation-related conditions. The potential addressable market is large, given the prevalence of diseases with an inflammatory component. The company's strategy post-fundraising will be critical, as it must balance the urgency of bringing products to market with the rigorous demands of regulatory compliance.
Investors should also consider macroeconomic factors, such as healthcare spending trends and regulatory changes, that could influence the company's performance. Additionally, the investor's perception of the company's valuation, as implied by the offering price, can signal market sentiment towards the company's future.
DENVER, Jan. 26, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (the “Company”), a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announced today that it has entered into a securities purchase agreement with a single institutional investor to purchase 10,840,761 shares of common stock (or pre-funded warrants in lieu thereof) in a registered direct offering. In a concurrent private placement, the Company also agreed to issue and sell to the investor Series A warrants to purchase up to an aggregate 10,840,761 shares of common stock, and Series B warrants to purchase up to an aggregate 5,420,381 shares of common stock. The combined effective offering price for each share of common stock (or pre-funded warrant in lieu thereof), accompanying Series A warrants and Series B warrants is
Maxim Group LLC is acting as the sole placement agent for the offering.
The offering is expected to close on or about January 30, 2024, subject to the satisfaction of customary closing conditions.
The shares of common stock and pre-funded warrants are being offered pursuant to a shelf registration statement on Form S-3 (File No. 333-275968) previously filed and declared effective by the Securities and Exchange Commission (SEC). The offering of the shares of common stock and pre-funded warrants will be made only by means of a prospectus supplement that forms a part of the registration statement. The warrants to be issued in the concurrent private placement and the shares issuable upon exercise of such warrants were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Act"), and Regulation D promulgated thereunder and have not been registered under the Act or applicable state securities laws.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. A prospectus supplement relating to the shares of common stock will be filed by the Company with the SEC. When available, copies of the prospectus supplement relating to the registered direct offering, together with the accompanying prospectus, can be obtained at the SEC's website at www.sec.gov or from Maxim Group LLC, 300 Park Avenue, New York, NY 10022, at (212) 895-3745.
About SeaStar Medical
SeaStar Medical is a medical technology company that is redefining how extracorporeal therapies may reduce the consequences of excessive inflammation on vital organs. SeaStar Medical’s novel technologies rely on science and innovation to provide life-saving solutions to critically ill patients. The Company is developing and commercializing cell-directed extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. For more information visit https://seastarmedical.com/ or visit us on LinkedIn or X (previously Twitter).
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1955. These forward-looking statements include, without limitation, SeaStar Medical’s expectations with respect to the offering and closing of the offering. Words such as “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside SeaStar Medical’s control and are difficult to predict. Factors that may cause actual future events to differ materially from the expected results include, but are not limited to, the risk that SeaStar Medical may not be able to obtain regulatory approval of its SCD product candidates, the risk that SeaStar Medical may not be able to raise sufficient capital to fund its operations, including clinical trials, the risk that SeaStar Medical and its current and future collaborators are unable to successfully develop and commercialize its products or services, or experience significant delays in doing so, including failure to achieve approval of its products by applicable federal and state regulators, the risk that SeaStar Medical may never achieve or sustain profitability, the risk that SeaStar Medical may not be able to access funding under existing agreements, including the equity line of credit and forward purchase agreements, the risk that third-parties suppliers and manufacturers are not able to fully and timely meet their obligations, the risk of product liability or regulatory lawsuits or proceedings relating to SeaStar Medical’s products and services, the risk that SeaStar Medical is unable to secure or protect its intellectual property, and other risks and uncertainties indicated from time to time in SeaStar Medical’s Annual Report on Form 10-K, including those under the “Risk Factors” section therein and in SeaStar Medical’s other filings with the SEC. The foregoing list of factors is not exhaustive. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and SeaStar Medical assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.
Contact:
LHA Investor Relations
Jody Cain
(310) 691-7100
Jcain@lhai.com
FAQ
What is the ticker symbol for SeaStar Medical Holding Corporation?
How many shares of common stock are being purchased in the registered direct offering?
What is the expected gross proceeds from the offering?
Who is acting as the sole placement agent for the offering?
